FINWIRES · TerminalLIVE
FINWIRES

研究快讯:WSP 第一季度:交易完成率提升 + EBITDA 利润率扩大 = 年初开局良好

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:WSP公布的季度业绩双双超出预期,净收入达37.09亿加元,略高于市场预期1%,同比增长10.8%;调整后每股收益为2.21加元,同比增长25.6%,高于市场预期7%。调整后EBITDA利润率提升80个基点至16.8%,调整后EBITDA增长16.5%至6.222亿加元,接近管理层预期范围的高端。5.0%的内生增长以及TRC和Ricardo收购带来的9.0%的收购增长推动了收入增长,调整后净利润增长29.9%至2.977亿加元。管理层指出,经调整上年同期保理收益后,自由现金流环比改善5000万加元,但自由现金流转为2900万加元的流出。TRC收购融资后,长期债务从34.418亿加元大幅增加至72.598亿加元,杠杆率也因此超过目标区间,达到2.3倍。积压订单达到197亿加元,同比增长19.0%,相当于11.5个月的收入;应收账款周转天数从70天改善至67天。

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661